Free Stock Research Report: URS Corp (URS)

Among the top institutional owners of engineering and construction firm URS Corp (NYSE:URS) are several hedge fund managers with an activist bent, such as Barry Rosenstein of JANA Partners, Larry Robbins of Glenview Capital Management, David Einhorn of Greenlight Capital, Clifton Robbins of Blue Harbour and Steven B. Klinsky of New Mountain Capital, most of whose stakes have increased during 4Q13.

Beating the market can be difficult when picking stocks on your own. One common source of alpha can be focusing on small cap stocks, which tend to outperform its larger peers over time. Another source of alpha can be following the smart money, by mimicking the trades of professional investors. Our research has shown that, by combining these two approaches – buying the most popular small-cap stocks recently purchased by hedge funds – one can outperform the market on average (read the details here).

URS Corp (NYSE:URS)

Last September, URS Corp (NYSE:URS) laid out plans to return $500M to shareholders by the end of 2015 through stock buybacks and dividends, funded internally from its free cash flow. More importantly, the company does not plan any major acquisitions over the next two years, which had been the largest use of its cash flow in the past (it has completed approximately $2B of acquisitions since the beginning of 2010). Coincidentally, this announcement came during a quarter in which several hedge funds purchased large amounts of the stock during the quarter. Assuming roughly $60M of annual dividend payments, its capital plan would imply share repurchases of $380M (or 11% of its market cap). Since the vast majority of the buybacks ($350M) will be completed in 2014, the impact to 2015 EPS should be maximized (at least $0.50 accretive, based on our estimate). URS does have $690M of debt maturing in Oct. 2016, which could decrease the amount of capital return to shareholders in that year but, as this debt is related to a credit facility (which tends to be maintained / refinanced for liquidity purposes rather than completely paid off), assuming URS’s business does not fall off a cliff, its cash flow generation and share repurchases should not deviate too much after 2015.

Following the company’s mid-February pre-announcement of disappointing 4Q13 results and lower-than-consensus 2014 guidance, due to execution issues in its Oil & Gas Division and project delays stemming from lower natural gas prices / pipeline capacity, the stock dropped 14% the next day and is down 12% YTD. With market expectations reset lower, URS has been setup for a rebound if it can demonstrate improved EPS through higher share repurchases.  Its free cash flow yield of 8.5% is double the level of peers but, as its capital allocation changes to one focused on returning cash to shareholders rather than growing through acquisitions, this disparity should narrow (a peer-like yield would imply a stock price more than double its current level). Any developments on increased ownership by activist investors, either new or existing, would also act as a positive catalyst.

After the market close on February 27, 2014, JANA Partners disclosed in a 13D filing that it increased its position by roughly 100,000 shares (for a 9.7% stake in the company) and will be taking on an activist role, with plans to increase shareholder value by discussing with management possible changes to its board, management, capital / corporate structure and other matters.

Disclosure: none

Recommended Reading:

Michael Zimmerman Is Betting on J.C. Penney Company (JCP), KKR Financial Holdings LLC (KFN) & Others

Free Stock Research Report: Allegion PLC (ALLE) 

Brian Sheehy and Iszo Capital’s Top Stock Picks

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!